1. Academic Validation
  2. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus

The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus

  • Diabetologia. 1999 Apr;42(4):465-71. doi: 10.1007/s001250051180.
T Kunt 1 S Schneider A Pfützner K Goitum M Engelbach B Schauf J Beyer T Forst
Affiliations

Affiliation

  • 1 Department of Endocrinology, University of Mainz, Germany.
Abstract

Aims/hypothesis: In recent years, evidence has arisen that proinsulin C-peptide exerts biological effects especially on microcirculation, e.g. C-peptide has been shown to increase skin microcirculation in patients with Type I (insulin-dependent) diabetes mellitus and to activate endothelial nitric oxide synthase. This study aimed to investigate the influence of pro-insulin C-peptide on erythrocyte deformability which was assessed by means of laser diffractoscopy.

Methods: Blood samples from healthy control subjects (n = 10) and Type I diabetic patients (n = 15) completely deficient of C-peptide were analysed at shear stresses ranging from 0.3 to 30 Pa.

Results: Erythrocyte deformability was lower in the group of Type I diabetic patients than in the control subjects. Preincubation of the diabetic blood samples with various concentrations of human proinsulin C-peptide for 8 h restored the deformability of erythrocytes, almost reaching the values of control samples. In contrast, proinsulin C-peptide did not modify the erythrocyte deformability of control subjects.

Conclusion/interpretation: We conclude that proinsulin C-peptide is able to ameliorate the impaired deformability of erythrocytes in Type I diabetic patients and we hypothesise that this effect is mediated by restoration of Na(+)-K(+)-ATPase activity, which is known to be attenuated in diabetic patients.

Figures
Products